Stryker Comprehensive Income 2010-2024 | SYK
Stryker comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Stryker comprehensive income for the quarter ending December 31, 2024 was $-0.293B, a 29.57% decline year-over-year.
- Stryker comprehensive income for 2024 was $-0.293B, a 29.57% decline from 2023.
- Stryker comprehensive income for 2023 was $-0.416B, a 88.24% increase from 2022.
- Stryker comprehensive income for 2022 was $-0.221B, a 58.38% decline from 2021.
| Stryker Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024 | $-293 |
| 2023 | $-416 |
| 2022 | $-221 |
| 2021 | $-531 |
| 2020 | $-1,157 |
| 2019 | $-606 |
| 2018 | $-631 |
| 2017 | $-553 |
| 2016 | $-761 |
| 2015 | $-639 |
| 2014 | $-254 |
| 2013 | $232 |
| 2012 | $129 |
| 2011 | $144 |
| 2010 | $154 |
| 2009 | $258 |
| Stryker Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-293 |
| 2024-09-30 | $-545 |
| 2024-06-30 | $-355 |
| 2024-03-31 | $-377 |
| 2023-12-31 | $-416 |
| 2023-09-30 | $-249 |
| 2023-06-30 | $-330 |
| 2023-03-31 | $-305 |
| 2022-12-31 | $-221 |
| 2022-09-30 | $-89 |
| 2022-06-30 | $-286 |
| 2022-03-31 | $-479 |
| 2021-12-31 | $-531 |
| 2021-09-30 | $-816 |
| 2021-06-30 | $-943 |
| 2021-03-31 | $-867 |
| 2020-12-31 | $-1,157 |
| 2020-09-30 | $-917 |
| 2020-06-30 | $-715 |
| 2020-03-31 | $-623 |
| 2019-12-31 | $-606 |
| 2019-09-30 | $-553 |
| 2019-06-30 | $-630 |
| 2019-03-31 | $-565 |
| 2018-12-31 | $-631 |
| 2018-09-30 | $-604 |
| 2018-06-30 | $-557 |
| 2018-03-31 | $-510 |
| 2017-12-31 | $-553 |
| 2017-09-30 | $-498 |
| 2017-06-30 | $-590 |
| 2017-03-31 | $-675 |
| 2016-12-31 | $-761 |
| 2016-09-30 | $-600 |
| 2016-06-30 | $-595 |
| 2016-03-31 | $-622 |
| 2015-12-31 | $-639 |
| 2015-09-30 | $-529 |
| 2015-06-30 | $-431 |
| 2015-03-31 | $-521 |
| 2014-12-31 | $-254 |
| 2014-09-30 | $-74 |
| 2014-06-30 | $231 |
| 2014-03-31 | $268 |
| 2013-12-31 | $232 |
| 2013-09-30 | $146 |
| 2013-06-30 | $31 |
| 2013-03-31 | $17 |
| 2012-12-31 | $129 |
| 2012-09-30 | $78 |
| 2012-06-30 | $-60 |
| 2012-03-31 | $235 |
| 2011-12-31 | $144 |
| 2011-09-30 | $272 |
| 2011-06-30 | $484 |
| 2011-03-31 | $416 |
| 2010-12-31 | $154 |
| 2010-09-30 | $210 |
| 2010-06-30 | $-52 |
| 2010-03-31 | $152 |
| 2009-12-31 | $258 |
| 2009-09-30 | $327 |
| 2009-06-30 | $189 |
| 2009-03-31 | $69 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $132.255B | $22.595B |
| Stryker Corporation is a medical device company operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg and Neurotechnology & Spine. Orthopaedic?products include implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg?products consists of surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment and reprocessed and remanufactured medical devices. Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $227.162B | 27.40 |
| Boston Scientific (BSX) | United States | $140.689B | 37.90 |
| EssilorLuxottica (ESLOY) | France | $128.431B | 0.00 |
| Medtronic (MDT) | Ireland | $105.938B | 15.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.424B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.151B | 26.20 |
| ResMed (RMD) | United States | $31.269B | 24.08 |
| Agilent Technologies (A) | United States | $29.217B | 19.30 |
| GE HealthCare Technologies (GEHC) | United States | $28.556B | 13.89 |
| Terumo (TRUMY) | Japan | $28.160B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.192B | 15.85 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.373B | 12.24 |
| Insulet (PODD) | United States | $17.332B | 74.11 |
| Baxter (BAX) | United States | $14.818B | 10.66 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.356B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $7.609B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.938B | 17.06 |
| Bio-Rad Laboratories (BIO) | United States | $6.672B | 23.10 |
| Demant (WILYY) | Denmark | $6.644B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.977B | 18.98 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.455B | 9.89 |
| ICU Medical (ICUI) | United States | $3.400B | 29.07 |
| Haemonetics (HAE) | United States | $2.872B | 13.52 |
| Envista Holdings (NVST) | United States | $2.614B | 20.80 |
| GN Store Nord (GNNDY) | Denmark | $2.188B | 14.75 |
| LeMaitre Vascular (LMAT) | United States | $1.946B | 44.47 |
| QuidelOrtho (QDEL) | United States | $1.698B | 14.22 |
| AtriCure (ATRC) | United States | $1.565B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.214B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.189B | 18.67 |
| AdaptHealth (AHCO) | United States | $1.051B | 10.12 |
| BioLife Solutions (BLFS) | United States | $1.041B | 0.00 |
| InMode (INMD) | Israel | $1.038B | 8.67 |
| Neogen (NEOG) | United States | $0.953B | 12.19 |
| Phibro Animal Health (PAHC) | United States | $0.700B | 10.74 |
| Evolus (EOLS) | United States | $0.686B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.649B | 0.00 |
| Valneva SE (VALN) | France | $0.552B | 0.00 |
| Owens & Minor (OMI) | United States | $0.535B | 4.56 |
| CeriBell (CBLL) | United States | $0.532B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.514B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.453B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.450B | 0.00 |
| Surmodics (SRDX) | United States | $0.394B | 0.00 |
| Omeros (OMER) | United States | $0.394B | 0.00 |
| SNDL (SNDL) | Canada | $0.368B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.328B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.302B | 13.07 |
| Viemed Healthcare (VMD) | United States | $0.262B | 23.68 |
| Sanara MedTech (SMTI) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 15.65 |
| Sanuwave Health (SNWV) | United States | $0.256B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.251B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.250B | 44.40 |
| Cerus (CERS) | United States | $0.242B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.224B | 0.00 |
| Quanterix (QTRX) | United States | $0.200B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.189B | 0.00 |
| High Tide (HITI) | Canada | $0.187B | 0.00 |
| Biote (BTMD) | United States | $0.181B | 4.12 |
| TriSalus Life Sciences (TLSI) | United States | $0.175B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.172B | 13.24 |
| Brainsway (BWAY) | Israel | $0.155B | 48.47 |
| Jin Medical (ZJYL) | China | $0.147B | 0.00 |
| Organigram Global (OGI) | Canada | $0.135B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.123B | 15.42 |
| Agape ATP (ATPC) | $0.094B | 0.00 | |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.086B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.083B | 0.00 |
| Exagen (XGN) | United States | $0.080B | 0.00 |
| MacroGenics (MGNX) | United States | $0.079B | 0.00 |
| Veru (VERU) | United States | $0.078B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.65 |
| Zynex (ZYXI) | United States | $0.066B | 24.22 |
| United Health Products (UEEC) | United States | $0.065B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 11.61 |
| Apyx Medical (APYX) | United States | $0.037B | 0.00 |
| Modular Medical (MODD) | United States | $0.036B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.035B | 51.50 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.010B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |